{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:52:41Z","timestamp":1792356761428,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006077.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000}}],"reference-count":79,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006077.pub3","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T16:35:55Z","timestamp":1413304555000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Allopurinol for chronic gout"],"prefix":"10.1002","volume":"2014","author":[{"given":"Rakhi","family":"Seth","sequence":"first","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust; Department of Rheumatology; Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison SR","family":"Kydd","sequence":"additional","affiliation":[{"name":"University of British Columbia; Division of Rheumatology; 1650 Terminal Ave, Suite 206 Nanaimo BC Canada V9S 0A3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology, Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[{"name":"Institute for Work & Health; 481 University Avenue, Suite 800 Toronto ON Canada M5G 2E9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust; Department of Rheumatology; Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"issue":"23","key":"10.1002\/14651858.CD006077.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Research Therapy"},{"issue":"9","key":"10.1002\/14651858.CD006077.pub3-BIB0003|cit3","first-page":"1246","article-title":"Intermittent control of hyperuricemia in the treatment of gout","volume":"16","author":"Bull","year":"1989","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD006077.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.41.1.59","article-title":"Allopurinol treatment and its effect on renal function in gout: a controlled study","volume":"41","author":"Gibson","year":"1982","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"Journal of Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD006077.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD006077.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1975.03240230017012","article-title":"Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose","volume":"231","author":"Rodnan","year":"1975","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD006077.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD006077.pub3-BIB0009|cit9","first-page":"623","article-title":"Comparison of allopurinol and probenecid","volume":"25","author":"Scott","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3329\/bjms.v10i4.7522","article-title":"Comparison between allopurinol and febuxostat in management of gout patients - a prospective study","volume":"10","author":"Singal","year":"2011","journal-title":"Bangladesh Journal of Medical Science"},{"issue":"11","key":"10.1002\/14651858.CD006077.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjmed.2012.05.025","article-title":"Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial","volume":"125","author":"Taylor","year":"2012","journal-title":"American Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006077.pub3-BIB0012|cit12","first-page":"1087","article-title":"The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia","volume":"87","author":"Akkasilpa","year":"2004","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"6","key":"10.1002\/14651858.CD006077.pub3-BIB0013|cit13","first-page":"86","article-title":"Comparative study of herbal medicine with allopathic medicine for the treatment of hyperuricemia","volume":"2","author":"Akram","year":"2010","journal-title":"Journal of Pharmacognosy and Phytotherapy"},{"issue":"11","key":"10.1002\/14651858.CD006077.pub3-BIB0014|cit14","first-page":"448","article-title":"Effect of allopurinol in gouty patients given long term corticotherapy","volume":"21","author":"Auscher","year":"1974","journal-title":"Biomedicine"},{"issue":"23","key":"10.1002\/14651858.CD006077.pub3-BIB0015|cit15","first-page":"719","article-title":"Effectiveness and tolerance of long-term uricosuric treatment [in German]","volume":"45","author":"Berg","year":"1990","journal-title":"Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete"},{"issue":"421","key":"10.1002\/14651858.CD006077.pub3-BIB0016|cit16","first-page":"606","article-title":"Allopurinol in treatment of patients with gout and chronic renal failure","volume":"66","author":"Bowie","year":"1967","journal-title":"New Zealand Medical Journal"},{"issue":"36","key":"10.1002\/14651858.CD006077.pub3-BIB0017|cit17","first-page":"4862","article-title":"Uric acid lowering effect of allopurinol (300 mg) in single or in fractionated dosage","volume":"25","author":"Bresnik","year":"1975","journal-title":"Therapiewoche"},{"issue":"3","key":"10.1002\/14651858.CD006077.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/ard.34.3.256","article-title":"Single daily dose of allopurinol","volume":"34","author":"Brewis","year":"1975","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3-4","key":"10.1002\/14651858.CD006077.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1142\/S0192415X95000316","article-title":"The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol","volume":"23","author":"Chou","year":"1995","journal-title":"American Journal of Chinese Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0020|cit20","first-page":"335","article-title":"Comparison of the urate lowering effects of allopurinol and diflunisal","volume":"14","author":"Emmerson","year":"1987","journal-title":"Journal of Rheumatology"},{"issue":"302","key":"10.1002\/14651858.CD006077.pub3-BIB0021|cit21","first-page":"409","article-title":"Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia","volume":"37","author":"Fraser","year":"1987","journal-title":"Journal of the Royal College of General Practitioners"},{"issue":"3","key":"10.1002\/14651858.CD006077.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/art.1780090306","article-title":"Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout","volume":"9","author":"Goldfarb","year":"1966","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006077.pub3-BIB0023|cit23","first-page":"40","article-title":"Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients","volume":"85","author":"Hanvivadhanakul","year":"2002","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006077.pub3-BIB0024|cit24","first-page":"S44","article-title":"An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study","volume":"17","author":"Kamatani","year":"2011","journal-title":"Journal of Clinical Rheumatology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006077.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","article-title":"An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study","volume":"17","author":"Kamatani","year":"2011","journal-title":"Journal of Clinical Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD006077.pub3-BIB0026|cit26","first-page":"177","article-title":"The influence of allopurinol on the course of gout. A study of 28 cases","volume":"8","author":"Kawenoki-Minc","year":"1970","journal-title":"Reumatologia"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD006077.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/ard.25.Suppl_6.643","article-title":"Allopurinol in primary gout with and after the administration of uricosuric agents","volume":"25","author":"Kersley","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD006077.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.25.Suppl_6.634","article-title":"Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone","volume":"25","author":"Kuzell","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006077.pub3-BIB0029|cit29","first-page":"460","article-title":"Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia","volume":"87","author":"Matzkies","year":"1992","journal-title":"Medizinische Klinik"},{"issue":"3-4","key":"10.1002\/14651858.CD006077.pub3-BIB0030|cit30","first-page":"111","article-title":"Use of milurit in the treatment of gout","volume":"21","author":"Mituszova","year":"1973","journal-title":"Therapia Hungarica"},{"issue":"1","key":"10.1002\/14651858.CD006077.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00315283","article-title":"The effect of benzbromarone on allopurinol\/oxypurinol kinetics in patients with gout","volume":"44","author":"Muller","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006077.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3949\/ccjm.35.3.145","article-title":"Treatment of gout and urate calculi with allopurinol","volume":"35","author":"O'Duffy","journal-title":"Cleveland Clinic Quarterly"},{"issue":"1","key":"10.1002\/14651858.CD006077.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0b013e318164dceb","article-title":"Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease","volume":"14","author":"Panomvana","year":"2008","journal-title":"Journal of Clinical Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD006077.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006077.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0254-6272(08)60023-0","article-title":"Treatment of 60 cases of gouty arthritis with modified Simiao Tang","volume":"28","author":"Qiu","year":"2008","journal-title":"Journal of Traditional Chinese Medicine"},{"issue":"5-6","key":"10.1002\/14651858.CD006077.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2298\/SARH1306333R","article-title":"The efficacy and tolerability of allopurinol dose escalation in patients with gout [in Serbian]","volume":"141","author":"Radak-Perovic","year":"2013","journal-title":"Srpski Arhiv za Celokupno Lekarstvo"},{"issue":"9","key":"10.1002\/14651858.CD006077.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clinical Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD006077.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006077.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level","volume":"90","author":"Stamp","year":"2011","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects","volume":"47","author":"Stocker","year":"2008","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1002\/14651858.CD006077.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Annals of the Rheumatic Disease"},{"issue":"10","key":"10.1002\/14651858.CD006077.pub3-BIB0045|cit45","first-page":"353","article-title":"Azapropazone or allopurinol in the treatment of chronic gout and\/or hyperuricaemia. A preliminary report","volume":"36","author":"Templeton","year":"1982","journal-title":"British Journal of Clinical Practice"},{"issue":"14","key":"10.1002\/14651858.CD006077.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1055\/s-0028-1103816","article-title":"Allopurinol in the treatment of gout and uric acid nephrolithiasis","volume":"92","author":"Z\u00f6llner","year":"1967","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD006077.pub3-BIB0047|cit47","first-page":"52","article-title":"Comparative evaluation of efficacy and safety profile of febuxostat with allopurinol in patients with hyperuricaemia and chronic gout","volume":"2","author":"Kumar","year":"2013","journal-title":"International Journal of Pharma Medicine and Biological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD006077.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.reuma.2010.02.001","article-title":"Systematic review: safety and efficacy of anti-TNF in elderly patients","volume":"7","author":"Busquets","year":"2011","journal-title":"Rheumatologica Clinica"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0050|cit50","unstructured":"Cates C Visual Rx Version 3 www.nntonline.net\/visualrx"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety and efficacy for hyperuricaemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Current Rheumatology Reports"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/BOR.0b013e328325bd94","article-title":"Update on emerging urate lowering therapies","volume":"21","author":"Chohan","year":"2009","journal-title":"Current Opinion in Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD006077.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Seminars in Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD006077.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/ard.2010.139899","article-title":"Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide","volume":"70","author":"Dalbeth","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0055|cit55","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD006077.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7","article-title":"Efficacy and safety of desensitization to allopurinol following cutaneous reactions","volume":"44","author":"Fam","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2013.05.004","article-title":"A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout","volume":"43","author":"Faruque","year":"2013","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"A","key":"10.1002\/14651858.CD006077.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-4615-9140-5_42","article-title":"A controlled study of the effect of long term allopurinol treatment on renal function in gout","volume":"122","author":"Gibson","year":"1980","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"6","key":"10.1002\/14651858.CD006077.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3810\/pgm.2011.11.2511","article-title":"Recommendations for the diagnosis and management of gout and hyperuricaemia","volume":"163","author":"Hamburger","year":"2011","journal-title":"Postgraduate Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006077.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/ard.2006.051649","article-title":"Sex differences in gout epidemiology: evaluation and treatment","volume":"65","author":"Harrold","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0061|cit61","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0062|cit62","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0063|cit63","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD006077.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD006077.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/rheumatology\/ker023","article-title":"Minimally important differences of the gout impact scale in a randomized controlled trial","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD006077.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Research"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0067|cit67","volume-title":"Rheumatology","author":"Klippel","year":"1994"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0068|cit68","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"21","key":"10.1002\/14651858.CD006077.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0070|cit70","unstructured":"Schumacher HR Edwards LN Perez-Ruiz F Becker M Chen LX Furst D Outcome measures for acute and chronic gout Proceedings of OMERACT 7; 2004 May 8-12; Asilomar (CA)"},{"issue":"10","key":"10.1002\/14651858.CD006077.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcomes domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0072|cit72","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0073|cit73","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD006077.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3899\/jrheum.110271","article-title":"Patient-reported outcomes in chronic gout: a report from OMERACT 10","volume":"38","author":"Singh","year":"2011","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0075|cit75","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD006077.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0889-857X(21)00975-3","article-title":"Therapy in gout","volume":"14","author":"Wallace","year":"1988","journal-title":"Rheumatic Diseases Clinics of North America"},{"issue":"3","key":"10.1002\/14651858.CD006077.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","article-title":"Gout and hyperuricaemia","volume":"14","author":"Wortmann","year":"2002","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD006077.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Annals of the Rheumatic Diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006077.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T03:34:32Z","timestamp":1696131272000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006077.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":79,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006077.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}